Phaseline

Companies › Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Genitourinary, Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nedosiran Sodium
L-lactate dehydrogenase A chain mRNA RNAi inhibitor
LDHAPhase 3Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 1Apr 2030
DCR-PDL1
PDL1 inhibitor delivered via RNAi
PDCD1LG1Phase 1Solid Tumors, AdultDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06504368DCR-PDL1Phase 1Solid Tumors, AdultOncologyDec 2027
NCT04042402Nedosiran SodiumPhase 3Primary Hyperoxaluria Type 1 (PH1)GenitourinaryApr 2030
NCT04580420Nedosiran SodiumPhase 2Primary Hyperoxaluria Type 1GenitourinaryDec 2031

Targets

LDHA (1) PDCD1LG1 (1)

Companies with the same targets

ImmunityBio Chia Tai Tianqing Pharmaceutical Group Pfizer MediLink Therapeutics (Suzhou)

Companies built like this

Hope Biosciences Shenzhen Kangzhe Biotechnology Norroy Bioscience Everest Medicines (China) Biocity Biopharmaceutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.